0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Angiopoietin-2

Angiopoietin-2

Angiopoietin-2 Molecule Information

Name:Angiopoietin-2
Target Synonym:Angiopoietin-2;ANGPT2;ANG-2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:11
Lastest Research Phase:Phase ?

Angiopoietin-2 Protein Product ListCompare or Buy

Angiopoietin-2 Molecule Synonym Name

ANGPT2,AGPT2,ANG2,Angiopoietin-2

Angiopoietin-2 Molecule Background

Angiopoietin-2 is also known as ANGPT2, AGPT2, ANG2, and is a secreted glycoprotein that plays a complex role in angiogenesis and inflammation. Ang2 is widely expressed during development, but it is restricted postnatally to highly angiogenic tissues such as the placenta, ovaries, and uterus. It is particularly abundant in vascular endothelial cells (EC) where it is stored in intracellular Weibel Palade bodies. Both Ang2 and the related Angiopoietin1 (Ang1) are ligands for the receptor tyrosine kinase Tie 2. Ang2 functions as a proangiogenic factor, although it can also induce EC death and vessel regression. Upon its release from quiescent EC, it regulates vascular remodeling by promoting EC survival, proliferation, and migration and destabilizing the interaction between EC and perivascular cells. Ang2 is required for postnatal vascular remodeling, and it cooperates with Ang1 during lymphatic vessel development. It mediates the upregulation of ICAM1 and VCAM1 on EC, which facilitates the adhesion of leukocytes during inflammation. Ang2 competitively inhibit Ang1-induced endothelial cell responses mediated by Tie2, and reduces vascular integrity. But the role of Ang2 is controversial since the opposite outcomes has been reported in other studies. Over-expression of Ang2 disrupts the vascular remodeling, induce endothelial cell apoptosis, and may play an important regulating role in tumor angiogenesis. Ang2 also promotes the neuronal differentiation and migration of subventricular zone progenitor cells.

Angiopoietin-2 References

Angiopoietin-2 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Faricimab RG-7716; RO-6867461 Phase Ⅲ Roche Diabetic macular edema, Wet age-related macular degeneration Details
AMG-780 AMG-780 Phase Ⅰ Amgen Solid tumours Details
PF-5057459 CovX-241; CVX-241; PF-05057459 Phase Ⅰ Pfizer Solid tumours Details
MEDI-3617 MEDI-3617; ANG-2-mAb; Anti-ANG-2-mAb,MEDI3617 Phase Ⅰ MedImmune Solid tumours, Melanoma Details
Trebananib AMG-386; 20060439 ,AMG386 Phase Ⅲ Amgen, Takeda Fallopian tube cancer, Peritoneum cancer, Ovarian cancer Details
PF-4856884 CovX 060; CVX-060; PF-04856884 Phase Ⅱ CovX Pharmaceuticals, Pfizer Solid tumours, Renal carcinoma Details
Vanucizumab RG-7221; RO-5520985; B800Z06O8K (UNII code),RG7221; RO5520985 Phase Ⅱ Roche Solid tumours, Colorectal cancer Details
Nesvacumab REGN-910; SAR-307746 Phase Ⅰ Regeneron Pharmaceutical, Sanofi Solid tumours Details
LY-3127804 LY-3127804,LY3127804 Phase Ⅰ Lilly Gastric cancer, Solid tumours, Hepatocellular carcinoma (HCC) Details
BI-836880 BI-836880 Phase Ⅰ Ablynx, Boehringer Ingelheim Solid tumours Details
Aflibercept/Nesvacumab REGN 910-3 Phase Ⅱ Regeneron Pharmaceutical, Bayer Diabetic macular edema, Wet age-related macular degeneration Details

This web search service is supported by Google Inc.

totop